Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M

May.08.2025
Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Smoore International has granted a total of 4.004 million shares to 49 employees under its share award and option plans. The package includes 1.614 million awarded shares and 2.39 million options exercisable at HK$13.52 per share, with a total value of HK$54.14 million.

On May 7, 2025, Smoore International Holdings Limited (HKEX: 6969) issued two announcements, declaring that it has granted stock awards and stock options to multiple key employees under the company's stock award plan and stock option plan, with an exercise price of HK$13.52 per share based on the closing price of the company's stock on the day of grant. The total amount of the award plan can reach HK$54.14 million.

 

The announcement stated that the company granted a total of 1,614,000 shares of bonus stock to 36 eligible participants (all of whom are employees of the group). The grant price for these bonus shares was zero, while the closing price of the company's stock on the day of grant was HK$13.52 per share.

 

Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Announcement Document | Image Source: Smoore International

 

The vesting period for these stock rewards is set between May 7, 2026 and May 7, 2029. The company stated that the number of shares granted to each recipient is based on their position, tenure, and performance evaluation results.

 

After this round of awards, according to the stock award plan, there are still 307,546,059 shares available for future grants.

 

In addition, on the same day, Smoore International also granted a total of 2,390,000 stock options to 13 eligible participants (all of whom are employees of the group) under the revised first public offering stock option plan.

 

Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Notice document | Image source: Smoore International

 

The exercise price for these stock options is set at HK$13.52 per share. The options are valid for a period of 10 years from the date of issuance, expiring on May 6, 2035. The vesting period for the options is from May 7, 2026 to May 7, 2029, and the specific exercise periods for different batches of options vary, with the latest exercise date being May 6, 2035. Similar to stock awards, the number of stock options granted is tied to the individual's rank, tenure, and performance evaluation results.

 

After this equity purchase, a total of 554,727,627 shares will be available for future grants based on the authorized limit of the equity purchase plan.

 

The company emphasized that the issuance of stock awards and stock options in this round must be accepted by the recipients before they can take effect, and are subject to clawback provisions outlined in each respective plan. Specifically, if the recipients terminate their employment, any unvested stock awards and stock options will be forfeited. The company's board of directors believes that these incentive measures will help boost employee motivation and cohesion, ultimately fostering continuous growth and value creation for the company.

 

According to the listing rules, the issuance does not require approval from the company's shareholders. The company also confirms that the recipients of the issuance are not directors, senior executives, major shareholders, or their affiliates.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
According to Bloomberg, Philip Morris International’s Zyn is facing growing competition in the U.S. nicotine pouch market as consumers shift toward moister alternatives such as British American Tobacco’s Velo Plus.
BATPMI
May.22
Malaysian Court Rules Liquid Nicotine Exemption Irrational, Renewing Vape Regulation Debate
Malaysian Court Rules Liquid Nicotine Exemption Irrational, Renewing Vape Regulation Debate
Malaysia’s High Court ruled that the government’s earlier decision to remove liquid nicotine from the country’s Poisons List was “irrational,” reigniting debate over vape regulation, illicit trade, and youth protection.
Regulations
May.18
 Arizona Rules Extend Across Alternative Nicotine Supply Chain, With Licensing From 2028
Arizona Rules Extend Across Alternative Nicotine Supply Chain, With Licensing From 2028
Arizona Governor Katie Hobbs has signed HB 4001, bringing alternative nicotine products under a new state regulatory framework that will require maker and distributor licensing from 2028 and ban packaging designs that could appeal to minors.
Regulations
Jun.23
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands has outlined what the newly approved UK Tobacco and Vapes Act 2026 means for retailers. The legislation received Royal Assent on April 29, 2026, and gives the Government powers to extend tobacco-style regulation to a wider range of products, including vaping products, heated tobacco, nicotine pouches and cigarette papers. Imperial Brands emphasized that most measures will be introduced in phases rather than taking effect immediately.
May.11 by 2FIRSTS.ai
NielsenIQ and Goldman Sachs Data Show Smokeless Was the Only Growing Major U.S. Nicotine Category
NielsenIQ and Goldman Sachs Data Show Smokeless Was the Only Growing Major U.S. Nicotine Category
NielsenIQ and Goldman Sachs data show U.S. smokeless nicotine product sales rose more than 8% year over year in the 52 weeks ended May 30, making it the only major nicotine category to record growth.
Market
Jun.23
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14